- The company aims to produce high-quality biosimilars at an affordable cost
- The process simplifies server management.
In order to automate its manufacturing plants in Nashik, Reliance Life Sciences (RLS) has signed a contract with ABB India. This facility will have manufacturing plants for plasma proteins, biopharmaceuticals, oncology pharmaceuticals, and vaccines.
ABB plans to provide the DCS on the latest Windows Server 2022 platform. It will ensure extended lifecycle support and best-in-class software management. This platform will offer an integration platform that brings together various plant components and areas and it also eliminates the need for multiple PLCs. This integration ensures a unified audit trail, integrated data reports, and streamlined operations, reducing maintenance, training needs, and inventory. Moreover, it simplifies third-party audits.
“Reliance Life Sciences has a tradition of leveraging automation technologies in its manufacturing processes, as part of its larger objectives in quality and productivity,” said K.V. Subramaniam, President of Reliance Life Sciences. “The partnership with ABB is not just part of this continuum, but also a step up in terms of virtualization and process control.”
“We are proud to partner with Reliance Life Sciences on this critical project. This collaboration will reinforce our position in the pharma and life sciences market, where, as a technology provider, we see tremendous potential for growth and innovation,” said G. Balaji, SVP, Head of Energy Industries, ABB India. “With India rapidly progressing as a prominent biopharmaceutical manufacturing hub, we find ourselves well-poised to ride the wave of the industrial revolution driven by the adoption of automation in these segments, which is pivotal for large-scale production with quality assurance.”
System 800xA® will be installed in a virtualised environment for RLS. This process simplifies server management. It also reduces the IT footprint and thus, resultant operational costs.
ABB’s multichannel remote I/O solutions will help to streamline data communication, reduce wiring, declutter the hardware footprint in the plant, and improve space utilisation and faster project execution.
By adopting ABB’s modular remote I/O solution RLS will achieve faster commissioning and process implementation with the ability to scale the capacity of the plant in the future.
By scaling up its manufacturing facilities, RLS is aiming to produce high-quality biosimilars at an affordable cost.
